A Phase 3 interventional study of RANGER™ Paclitaxel Coated Balloon and Paclitaxel in Peripheral Artery Disease, Atherosclerosis and Artery Diseases, Peripheral, sponsored by Boston Scientific Corporation. Completed at 67 sites in 6 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-10-29.
Sponsored by Boston Scientific Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 25th largest by enrollment of the 373 interventional ones that give a count, is one of 38 that started in 2017, is one of 31 in phase 3, and was the 238th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, United Kingdom
Ages 18+
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+
Cook Research Incorporated · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 38 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 57 (88%) have results posted.
Boston Scientific Corporation has 7 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA).
Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
The RANGER II SFA is a global, prospective, multi-center clinical trial. Approximately 446 subjects will be enrolled at up to 80 study centers worldwide. Regions participating include the United States, Canada, European Union, Japan and New Zealand.
The trial consists of a single-blind, superiority, 3:1 (Ranger Drug-Coated Balloon (DCB) vs. Standard PTA) randomized controlled trial (RCT) and a concurrent, non-randomized, single-arm, pharmacokinetic (PK) substudy, and a concurrent, non-blinded, non-randomized, Long balloon substudy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Angiographic evidence that target lesion consists of a single de novo, non-stented and non-atherectomy treated or restenotic lesion (or tandem lesions or a combination lesion as defined below) that is:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
Device: RANGER™ Paclitaxel Coated Balloon · Drug: Paclitaxel
Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
Procedure: Standard Balloon Angioplasty
A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a "balloon" at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.
Also known as: Percutaneous Transluminal Angioplasty (PTA)
The RANGER™ Balloon is coated with the drug Paclitaxel.
A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a "balloon" at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries.
Also known as: Percutaneous Transluminal Angioplasty (PTA)
Number of Participants With Primary Lesion Patency
RCT outcome measure: Primary patency of the target lesion is determined by Peak Systolic Velocity Ratio (PSVR) ≤ 2.4 (by duplex ultrasound (DUS)) and freedom from clinically-driven Target Lesion Revascularization (TLR) within 12 months from procedure. Lesion patency is defined as freedom from more than 50% stenosis based on DUS PSVR comparing data within the treated segment to the proximal normal arterial segment. PSVR \>2.4 suggests \>50% stenosis. LB Substudy outcome measure: Primary patency of the target lesion is determined by duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≤ 2.4 in absence of clinically-driven TLR. Primary effectiveness endpoint is assessed at 6 months post-procedure. PK Substudy: There was no prespecified analysis of primary lesion patency.
Time frame: 12 months (RCT); 6 months (LB substudy)
Major Adverse Events (MAEs) (Primary Safety Endpoint)
RCT: MAE is defined as a composite of freedom from all-cause death through 1 month, target limb major amputation (defined as at or above the ankle) within 12 months, and/or Target Lesion Revascularization (TLR) within 12 months. LB Substudy: Primary safety endpoint assesses the occurrence of MAE defined as all-cause death through 1 month, target limb major amputation and/or TLR at 6 and 12 months post-index procedure. PK Substudy: There was no prespecified analysis of primary safety endpoint.
Time frame: Primary safety endpoint assessed at 12 months for RCT study and at both 6 and 12 months for LB substudy.
Number of Participants With Technical Success of Angioplasty Procedure
Technical success defined as successful delivery, balloon inflation and deflation and retrieval of the intact trial device without burst below the rated burst pressure. RCT Standard Balloon Angioplasty: Device deficiency data is only collected for Ranger DCB; data not collected for Standard PTA group; there is no pre-specified analysis of this outcome for the Standard PTA group.
Time frame: Day 0
Number of Participants With Procedural Success of Angioplasty Procedure
Procedural success defined as residual stenosis of less than or equal to 50% (non-stented subjects) or less than or equal to 30% (stented subjects) by core laboratory evaluation.
Time frame: Day 0
Number of Participants With Clinical Success Rate Assessment
Clinical success defined as procedural success without procedural complications including death, major target limb amputation, thrombosis of the target lesion, or clinically-driven TLR prior to discharge.
Time frame: Day 0
Number of Major Adverse Event (MAE) Assessment
MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 60-months in RCT. MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 12-months in LB substudy. PK Substudy: There was no prespecified analysis of MAEs for PK substudy.
Time frame: 60-months (RCT); 12-months (LB substudy).
Number of Clinical Events Committee (CEC) Adjudicated Events
CEC adjudicated events including death of any cause, target lesion revascularization (TLR), target vessel revascularization (TVR) and target limb amputation (TLA). Denominators for the cumulative rate will be based on 1) subjects with events, and 2) subjects with no events but their follow-up time reaches (or is beyond) the earliest visit window. LB substudy follow-up through 12 month.
Time frame: 1, 6, 12, 24, 36, 48 and 60 months (RCT and PK substudy); 1, 6 and 12 months (LB substudy)
Number of Participants With Rate of Primary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline
Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure without the need for repeat TLR. LB Substudy: Follow-up through 12-month. PK Substudy: There was no prespecified analysis of Rate of Primary Sustained Clinical Improvement for PK substudy.
Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT); 1, 6 and 12 months post-procedure (LB substudy).
Number of Participants With Rate of Secondary Sustained Clinical Improvement as Assessed by Changes in Rutherford Classification From Baseline.
Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure including those subjects with repeat TLR. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Secondary Sustained Clinical Improvement for PK substudy.
Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT): 1, 6, and 12 months post-procedure (LB substudy)
Number of Participants With Rate of Hemodynamic Improvement as Assessed by Changes in Ankle Brachial Index (ABI) From Baseline.
Improvement of ABI by ≥ 0.1 or to an ABI ≥ 0.90 as compared to the pre-procedure value without the need for repeat revascularization. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Hemodynamic Improvement for PK substudy.
Time frame: 1, 6, 12, 24, and 36 months post-procedure (RCT); 1, 6, and 12 months post-procedure (LB substudy)
Walking Improvement (Distance) at 6 and 12 Months as Assessed by Change in Six Minute Walk Test (6MWT) From Baseline
The 6MWT measure the maximal walking distance that a patient achieves on a flat, hard surface within a period of 6 minutes. It evaluates the global and integrated responses of all physiological systems involved during exercise including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, neuromuscular units and muscle metabolism. Change in distance walked from baseline to 12 months. LB Substudy: There was no prespecified analysis of Walking Improvement (distance) for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement (distance) for PK substudy.
Time frame: 6 and 12 months post-procedure (RCT)
Walking Improvement Assessed by Change in Walking Impairment Questionnaire (WIQ) From Baseline.
The WIQ is a functional assessment questionnaire that evaluates walking ability with regard to speed, distance and stair climbing ability. It also assesses the reasons that walking ability might be limited. Range of scores include 0% (worst score) to 100% (best score). Walking improvement change assessed from baseline. LB Substudy: There was no prespecified analysis of Walking Improvement for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement for the PK substudy.
Time frame: 1, 6, 12, 24 and 36 months post-procedure (RCT)
Duplex-defined Binary Restenosis (PSVR > 2.4) of the Target Lesion
Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, 12, 24 and 36 Months (RCT) Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, and 12 (LB Substudy) PK Substudy: There was no prespecified analysis of duplex defined binary restenosis of the target lesion
Time frame: 1, 6, 12, 24, and 36-months post-procedure (RCT); 1, 6, and 12-months post-procedure (LB substudy)
Patient Utility Values as Assessed by Change in EQ-5D From Baseline.
Patient Utility Values as assessed by change in EQ-5D from baseline at 1, 6, 12, 24 and 36-months post-procedure. The EuroQOL (EQ)-5D is a multi-attribute health classification system. The EQ-5D uses a 5-dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) descriptive system, which each consisting of 5 response options (no problems, slight problems, moderate problems, severe problems, or extreme problems/inability to perform). Outcomes reported as "Improvement" defined as improving at least one category from baseline. LB Substudy: There was no prespecified analysis of Patient Utility Values for the LB Substudy. PK Substudy: There was no prespecified analysis of Patient Utility Values for the PK Substudy.
Time frame: 1, 6, 12, 24 and 36-months post-procedure (RCT).
Changes in Healthcare Utilization Over Time
Changes in healthcare utilization over time as measured by hospitalization readmission. Readmission Rate represents (# of subjects/Total enrolled subjects) who were hospitalized due to TLR/TVR or due to Procedure/Device related AE. LB Substudy: Follow-up through 12 Month. PK Substudy: There was no prespecified analysis of healthcare utilization over time for the PK Substudy.
Time frame: 1, 6, 12, 24, 36, 48 and 60-months post-procedure (RCT); 1, 6, 12-months post-procedure (LB substudy)
PK Parameters Paclitaxel (PTx) Dose
Summary of Pharmacokinetic Parameters in PK substudy. Paclitaxel (PTx) Dose PK parameter data not collected or analyzed in RCT or LB substudy.
Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
PK Parameters - Maximum Plasma Concentration
Summary of Pharmacokinetic Parameters in PK substudy. cmax (ng/mL) = Maximum plasma concentration PK data not collected or analyzed in RCT or LB substudy.
Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
PK Parameters - Tmax
Summary of Pharmacokinetic Parameters in PK substudy. - Tmax Tmax (h) = The timepoint where cmax is reached PK parameter data not collected or analyzed in RCT or LB substudy.
Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
PK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods.
Summary of Pharmacokinetic Parameters in PK substudy. AUC0-t (ng\*h/mL) = Area under the blood concentration versus time curve from time zero up to the time of the last quantifiable concentration, calculated by trapezoidal methods. PK parameter data not collected or analyzed in RCT or LB substudy.
Time frame: Time points for analysis are a venous blood draw at screening, followed by blood draws at 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours and 24 or 48 hours after last Ranger DCB balloon removal, as well as 7 days and 30 days post index procedure.
| Milestone | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| Started | 278 | 98 | 52 | 12 |
| Completed | 203 | 67 | 48 | 8 |
| Not completed | 75 | 31 | 4 | 4 |
| Withdrew: Death | 40 | 16 | 4 | 2 |
| Withdrew: Withdrawal by subject | 17 | 9 | 0 | 2 |
| Withdrew: Lost to follow-up | 7 | 3 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 | 0 |
| Withdrew: Other reason for early termination | 3 | 2 | 0 | 0 |
| Withdrew: Missed visit | 3 | 1 | 0 | 0 |
RCT outcome measure: Primary patency of the target lesion is determined by Peak Systolic Velocity Ratio (PSVR) ≤ 2.4 (by duplex ultrasound (DUS)) and freedom from clinically-driven Target Lesion Revascularization (TLR) within 12 months from procedure. Lesion patency is defined as freedom from more than 50% stenosis based on DUS PSVR comparing data within the treated segment to the proximal normal arterial segment. PSVR \>2.4 suggests \>50% stenosis. LB Substudy outcome measure: Primary patency of the target lesion is determined by duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≤ 2.4 in absence of clinically-driven TLR. Primary effectiveness endpoint is assessed at 6 months post-procedure. PK Substudy: There was no prespecified analysis of primary lesion patency.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| Number of Participants With Primary Lesion Patency | 194 | 57 | 43 |
RCT: MAE is defined as a composite of freedom from all-cause death through 1 month, target limb major amputation (defined as at or above the ankle) within 12 months, and/or Target Lesion Revascularization (TLR) within 12 months. LB Substudy: Primary safety endpoint assesses the occurrence of MAE defined as all-cause death through 1 month, target limb major amputation and/or TLR at 6 and 12 months post-index procedure. PK Substudy: There was no prespecified analysis of primary safety endpoint.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 6 Month Primary Safety Endpoint | — | — | 50 |
| 12 Month Primary Safety Endpoint | 241 | 76 | 47 |
Technical success defined as successful delivery, balloon inflation and deflation and retrieval of the intact trial device without burst below the rated burst pressure. RCT Standard Balloon Angioplasty: Device deficiency data is only collected for Ranger DCB; data not collected for Standard PTA group; there is no pre-specified analysis of this outcome for the Standard PTA group.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| Number of Participants With Technical Success of Angioplasty Procedure | 277 | — | 47 | 12 |
Procedural success defined as residual stenosis of less than or equal to 50% (non-stented subjects) or less than or equal to 30% (stented subjects) by core laboratory evaluation.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| Number of Participants With Procedural Success of Angioplasty Procedure | 269 | 97 | 49 | 12 |
Clinical success defined as procedural success without procedural complications including death, major target limb amputation, thrombosis of the target lesion, or clinically-driven TLR prior to discharge.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| Number of Participants With Clinical Success Rate Assessment | 267 | 96 | 48 | 11 |
MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 60-months in RCT. MAEs defined as all-cause of death post-index procedure (30-days), target limb major amputation, and/or target lesion revascularization (TLR) through 12-months in LB substudy. PK Substudy: There was no prespecified analysis of MAEs for PK substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 12-Month MAE (Composite Endpoint) | 15 | 15 | 3 |
| 12-Month All Causes of Death at 1-Month | 1 | 0 | 0 |
| 12-Month Target Limb Major Amputation | 0 | 0 | 0 |
| 12-Month Target Lesion Revascularization | 14 | 15 | 3 |
| 60-Month MAE (Composite Endpoint) | 57 | 23 | — |
| 60-Month All Causes of Death at 1-Month | 1 | 0 | — |
| 60-Month Target Limb Major Amputation | 1 | 0 | — |
| 60-Month Target Lesion Revascularization | 56 | 23 | — |
CEC adjudicated events including death of any cause, target lesion revascularization (TLR), target vessel revascularization (TVR) and target limb amputation (TLA). Denominators for the cumulative rate will be based on 1) subjects with events, and 2) subjects with no events but their follow-up time reaches (or is beyond) the earliest visit window. LB substudy follow-up through 12 month.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| 1-Month All Deaths | 1 | 0 | 0 | 0 |
| 1-Month All Target Lesion Revascularization (TLR) | 0 | 0 | 1 | 0 |
| 1-Month All Target Vessel Revascularization (TVR) | 0 | 0 | 1 | 0 |
| 1-Month All Target Limb Amputation | 0 | 0 | 0 | 0 |
| 6-Month All Deaths | 3 | 2 | 2 | 1 |
| 6-Month All Target Lesion Revascularization (TLR) | 2 | 3 | 1 | 0 |
| 6-Month All Target Vessel Revascularization (TVR) | 3 | 3 | 1 | 0 |
| 6-Month All Target Limb Amputation | 1 | 0 | 0 | 0 |
| 12- Month All Deaths | 5 | 2 | 3 | 1 |
| 12-Month All Target Lesion Revascularization (TLR) | 14 | 15 | 3 | 2 |
| 12-Month All Target Vessel Revascularization (TVR) | 16 | 15 | 3 | 3 |
| 12-Month All Target Limb Amputation | 1 | 0 | 0 | 1 |
| 24-Month All Deaths | 14 | 3 | — | 1 |
| 24-Month All Target Lesion Revascularization (TLR) | 32 | 19 | — | 3 |
| 24-Month All Target Vessel Revascularization (TVR) | 38 | 20 | — | 4 |
| 24-Month All Target Limb Amputation | 1 | 1 | — | 1 |
| 36-Month All Deaths | 29 | 5 | — | 1 |
| 36-Month All Target Lesion Revascularization (TLR) | 42 | 21 | — | 3 |
| 36-Month All Target Vessel Revascularization (TVR) | 49 | 23 | — | 4 |
| 36-Month All Target Limb Amputation | 1 | 3 | — | 1 |
| 48-Month All Deaths | 36 | 10 | — | 2 |
| 48-Month All Target Lesion Revascularization (TLR) | 52 | 23 | — | 3 |
| 48-Month All Target Vessel Revascularization (TVR) | 60 | 26 | — | 4 |
| 48-Month All Target Limb Amputation | 2 | 3 | — | 1 |
| 60-Month All Deaths | 40 | 16 | — | 2 |
| 60-Month All Target Lesion Revascularization (TLR) | 56 | 23 | — | 3 |
| 60-Month All Target Vessel Revascularization (TVR) | 64 | 26 | — | 4 |
| 60-Month All Target Limb Amputation | 3 | 3 | — | 1 |
Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure without the need for repeat TLR. LB Substudy: Follow-up through 12-month. PK Substudy: There was no prespecified analysis of Rate of Primary Sustained Clinical Improvement for PK substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 1-Month Primary Sustained Clinical Improvement | 256 | 91 | 50 |
| 6-Month Primary Sustained Clinical Improvement | 249 | 83 | 48 |
| 12-Month Primary Sustained Clinical Improvement | 222 | 69 | 45 |
| 24-Month Primary Sustained Clinical Improvement | 180 | 59 | — |
| 36-Month Primary Sustained Clinical Improvement | 150 | 53 | — |
Endpoint determined to be a success when there is an improvement in Rutherford Classification of one or more categories as compared to pre-procedure including those subjects with repeat TLR. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Secondary Sustained Clinical Improvement for PK substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 1-Month Secondary Sustained Clinical Improvement | 256 | 91 | 51 |
| 6-Month Secondary Sustained Clinical Improvement | 251 | 85 | 48 |
| 12-Month Secondary Sustained Clinical Improvement | 230 | 81 | 47 |
| 24-Month Secondary Sustained Clinical Improvement | 205 | 73 | — |
| 36-Month Secondary Sustained Clinical Improvement | 176 | 67 | — |
Improvement of ABI by ≥ 0.1 or to an ABI ≥ 0.90 as compared to the pre-procedure value without the need for repeat revascularization. LB Substudy: Follow-up through 12-months. PK Substudy: There was no prespecified analysis of Rate of Hemodynamic Improvement for PK substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 1-Month Hemodynamic Improvement | 252 | 83 | 43 |
| 6-Month Hemodynamic Improvement | 230 | 66 | 43 |
| 12-Month Hemodynamic Improvement | 202 | 57 | 40 |
| 24-Month Hemodynamic Improvement | 166 | 47 | — |
| 36-Month Hemodynamic Improvement | 128 | 45 | — |
The 6MWT measure the maximal walking distance that a patient achieves on a flat, hard surface within a period of 6 minutes. It evaluates the global and integrated responses of all physiological systems involved during exercise including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, neuromuscular units and muscle metabolism. Change in distance walked from baseline to 12 months. LB Substudy: There was no prespecified analysis of Walking Improvement (distance) for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement (distance) for PK substudy.
| Meters | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT |
|---|---|---|
| 6-Month Walking Improvement (Distance) | 40.7 ± 179.0 | 55.9 ± 117.5 |
| 12-Month Walking Improvement (Distance) | 36.3 ± 162.2 | 46.1 ± 115.4 |
The WIQ is a functional assessment questionnaire that evaluates walking ability with regard to speed, distance and stair climbing ability. It also assesses the reasons that walking ability might be limited. Range of scores include 0% (worst score) to 100% (best score). Walking improvement change assessed from baseline. LB Substudy: There was no prespecified analysis of Walking Improvement for the LB substudy. PK Substudy: There was no prespecified analysis of Walking Improvement for the PK substudy.
| Percentage increase | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT |
|---|---|---|
| 1-Month Walking Improvement Scoring Summary | 33.61 ± 35.78 | 34.47 ± 35.20 |
| 6-Month Walking Improvement Scoring Summary | 32.25 ± 37.07 | 32.25 ± 37.07 |
| 12-Month Walking Improvement Scoring Summary | 32.06 ± 39.49 | 34.72 ± 36.85 |
| 24-Month Walking Improvement Scoring Summary | 29.50 ± 36.87 | 29.76 ± 41.88 |
| 36-Month Walking Improvement | 30.37 ± 38.85 | 34.93 ± 39.03 |
Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, 12, 24 and 36 Months (RCT) Duplex-defined binary restenosis (PSVR \> 2.4) of the target lesion at 1, 6, and 12 (LB Substudy) PK Substudy: There was no prespecified analysis of duplex defined binary restenosis of the target lesion
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 1-month PSVR > 2.4 | 7 | 0 | 3 |
| 6-month PSVR > 2.4 | 8 | 12 | 2 |
| 12-month PSVR > 2.4 | 21 | 8 | 3 |
| 24-month PSVR > 2.4 | 17 | 6 | — |
| 36-month PSVR > 2.4 | 17 | 5 | — |
Patient Utility Values as assessed by change in EQ-5D from baseline at 1, 6, 12, 24 and 36-months post-procedure. The EuroQOL (EQ)-5D is a multi-attribute health classification system. The EQ-5D uses a 5-dimension (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) descriptive system, which each consisting of 5 response options (no problems, slight problems, moderate problems, severe problems, or extreme problems/inability to perform). Outcomes reported as "Improvement" defined as improving at least one category from baseline. LB Substudy: There was no prespecified analysis of Patient Utility Values for the LB Substudy. PK Substudy: There was no prespecified analysis of Patient Utility Values for the PK Substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT |
|---|---|---|
| 1-Month Mobility Improvement | 149 | 52 |
| 1-Month Self-Care Improvement | 24 | 12 |
| 1-Month Usual Activities Improvement | 107 | 44 |
| 1-Month Pain/Discomfort Improvement | 141 | 61 |
| 1-Month Anxiety/Depression Improvement | 55 | 23 |
| 6-Months Mobility Improvement | 149 | 45 |
| 6-Month Self-Care Improvement | 27 | 10 |
| 6-Month Usual Activities Improvement | 102 | 38 |
| 6-Month Pain/Discomfort Improvement | 126 | 47 |
| 6-Month Anxiety/Depression Improvement | 61 | 24 |
| 12-Months Mobility Improvement | 140 | 48 |
| 12-Month Self-Care Improvement | 26 | 14 |
| 12-Month Usual Activities Improvement | 94 | 41 |
| 12-Month Pain/Discomfort Improvement | 132 | 51 |
| 12-Month Anxiety/Depression Improvement | 59 | 22 |
| 24-Months Mobility Improvement | 109 | 42 |
| 24-Month Self-Care Improvement | 17 | 12 |
| 24-Month Usual Activities Improvement | 87 | 38 |
| 24-Month Pain/Discomfort Improvement | 108 | 48 |
| 24-Month Anxiety/Depression Improvement | 47 | 17 |
| 36-Months Mobility Improvement | 100 | 37 |
| 36-Month Self-Care Improvement | 17 | 8 |
| 36-Month Usual Activities Improvement | 80 | 32 |
| 36-Month Pain/Discomfort Improvement | 96 | 38 |
| 36-Month Anxiety/Depression Improvement | 54 | 16 |
Changes in healthcare utilization over time as measured by hospitalization readmission. Readmission Rate represents (# of subjects/Total enrolled subjects) who were hospitalized due to TLR/TVR or due to Procedure/Device related AE. LB Substudy: Follow-up through 12 Month. PK Substudy: There was no prespecified analysis of healthcare utilization over time for the PK Substudy.
| Participants | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy |
|---|---|---|---|
| 1-Month Readmission Rate | 6 | 4 | 1 |
| 6-month Readmission Rate | 8 | 5 | 1 |
| 12-Month Readmission Rate | 18 | 9 | 3 |
| 24-Month Readmission Rate | 28 | 13 | — |
| 36-month Readmission Rate | 33 | 15 | — |
| 48-Month Readmission Rate | 37 | 16 | — |
| 60-Month Readmission Rate | 41 | 16 | — |
Summary of Pharmacokinetic Parameters in PK substudy. Paclitaxel (PTx) Dose PK parameter data not collected or analyzed in RCT or LB substudy.
| μg | Pharmacokinetics (PK) Substudy |
|---|---|
| PK Parameters Paclitaxel (PTx) Dose | 6136.6 ± 2554.3 |
Summary of Pharmacokinetic Parameters in PK substudy. cmax (ng/mL) = Maximum plasma concentration PK data not collected or analyzed in RCT or LB substudy.
| ng/mL | Pharmacokinetics (PK) Substudy |
|---|---|
| PK Parameters - Maximum Plasma Concentration | 2.50 ± 2.17 |
Summary of Pharmacokinetic Parameters in PK substudy. - Tmax Tmax (h) = The timepoint where cmax is reached PK parameter data not collected or analyzed in RCT or LB substudy.
| hours (h) | Pharmacokinetics (PK) Substudy |
|---|---|
| PK Parameters - Tmax | 0.17 ± 0 |
Summary of Pharmacokinetic Parameters in PK substudy. AUC0-t (ng\*h/mL) = Area under the blood concentration versus time curve from time zero up to the time of the last quantifiable concentration, calculated by trapezoidal methods. PK parameter data not collected or analyzed in RCT or LB substudy.
| ng*h/mL | Pharmacokinetics (PK) Substudy |
|---|---|
| PK Parameters - Area Under the Blood Concentration Versus Time Curve From Time Zero up to the Time of the Last Quantifiable Concentration, Calculated by Trapezoidal Methods. | 0.86 ± 0.76 |
Collected over Adverse event data collected through five-year (60-month) post-index procedure in RCT and PK substudy. Adverse event data collected through 12-month post index procedure in LB substudy All-Cause crude mortality includes deaths confirmed through survival status assessments.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RANGER™ Paclitaxel Coated Balloon | 44/278 (15.8%) | 212/278 (76.3%) | 176/278 (63.3%) |
| Standard Balloon Angioplasty | 20/98 (20.4%) | 73/98 (74.5%) | 63/98 (64.3%) |
| Long Balloon (LB) Substudy | 2/52 (3.8%) | 23/52 (44.2%) | 26/52 (50%) |
| Pharmacokinetics (PK) Substudy | 3/12 (25%) | 10/12 (83.3%) | 9/12 (75%) |
| Event | RANGER™ Paclitaxel Coated Balloon | Standard Balloon Angioplasty | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 5/278 | 1/98 | 0/52 | 3/12 |
| PneumoniaInfections and infestations | 15/278 | 9/98 | 4/52 | 3/12 |
| Peripheral artery stenosisVascular disorders | 63/278 | 18/98 | 7/52 | 0/12 |
| Coronary artery diseaseCardiac disorders | 12/278 | 4/98 | 1/52 | 2/12 |
| Oedema peripheralGeneral disorders | 1/278 | 0/98 | 0/52 | 2/12 |
| Acute kidney injuryRenal and urinary disorders | 11/278 | 4/98 | 0/52 | 2/12 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 3/278 | 1/98 | 0/52 | 2/12 |
| Hypertensive crisisVascular disorders | 1/278 | 1/98 | 0/52 | 2/12 |
| Peripheral arterial occlusive diseaseVascular disorders | 14/278 | 8/98 | 0/52 | 2/12 |
| HypertensionVascular disorders | 1/278 | 0/98 | 0/52 | 2/12 |
| Event | RANGER™ Paclitaxel Coated Balloon | Standard Balloon Angioplasty | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 9/278 | 4/98 | 2/52 | 4/12 |
| ConstipationGastrointestinal disorders | 2/278 | 2/98 | 0/52 | 2/12 |
| Peripheral artery stenosisVascular disorders | 17/278 | 6/98 | 6/52 | 2/12 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/278 | 0/98 | 0/52 | 2/12 |
| Intermittent claudicationVascular disorders | 31/278 | 11/98 | 2/52 | 1/12 |
| Atrial fibrillationCardiac disorders | 3/278 | 0/98 | 0/52 | 1/12 |
| TinnitusEar and labyrinth disorders | 1/278 | 0/98 | 0/52 | 1/12 |
| Catheter site haematomaGeneral disorders | 1/278 | 2/98 | 1/52 | 1/12 |
| OedemaGeneral disorders | 0/278 | 1/98 | 0/52 | 1/12 |
| CellulitisInfections and infestations | 5/278 | 2/98 | 0/52 | 1/12 |
| Age, Continuous(Years) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Mean | 70.6 ± 9.5 | 69.1 ± 10.3 | 70.3 ± 9.9 | 63.3 ± 13.3 | 70.06 ± 9.87 |
| Sex: Female, Male(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Female | 105 | 31 | 14 | 8 | 158 |
| Male | 173 | 67 | 38 | 4 | 282 |
| Race/Ethnicity, Customized(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 21 | 8 | 0 | 0 | 29 |
| Caucasian | 155 | 59 | 51 | 9 | 274 |
| Asian (Japanese) | 77 | 25 | 0 | 0 | 102 |
| Black, or African Heritage | 20 | 4 | 1 | 3 | 28 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 0 | 1 |
| Not Disclosed | 3 | 2 | 0 | 0 | 5 |
| Region of Enrollment(participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| New Zealand | 7 | 2 | 2 | 0 | 11 |
| Canada | 12 | 4 | 0 | 0 | 16 |
| Europe | 29 | 8 | 50 | 0 | 87 |
| Japan | 77 | 25 | 0 | 0 | 102 |
| United States | 153 | 59 | 0 | 12 | 224 |
| History of Smoking (Current)(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Count of participants | 87 | 45 | 24 | 6 | 162 |
| History of Smoking (Previous)(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Count of participants | 150 | 38 | 23 | 5 | 216 |
| History of Smoking (Never)(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Count of participants | 40 | 15 | 5 | 1 | 61 |
| History of Smoking (Unknown)(Participants) | RANGER™ Paclitaxel Coated Balloon RCT | Standard Balloon Angioplasty RCT | Long Balloon (LB) Substudy | Pharmacokinetics (PK) Substudy | Total |
|---|---|---|---|---|---|
| Count of participants | 1 | 0 | 0 | 0 | 1 |
21 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Nov 2019, 32 months.
Results were first posted in Jul 2020, 7 months after primary completion.
Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paclitaxel
Boston Scientific Corporation →